Loading
Life sciences · Journal article
Anticancer Research · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Aim: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy has demonstrated efficacy in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) failure. However, real-world evidence in the osimertinib era remains limited. This study aimed to evaluate the efficacy, safety, and prognostic factors of ABCP therapy in patients with EGFR-mutated NSCLC. Patients and Methods: This retrospective study evaluated patients with EGFR-mutated NSCLC who received ABCP therapy after EGFR-TKI failure at two institutions between January 1, 2019 and March 31, 2025. Progression-free survival (PFS), overall survival (OS), treatment response, and safety were evaluated, and prognostic factors were identified. Results: Sixty-one patients were evaluated. The median PFS and OS were 6.9 months [95% confidence interval (CI)=4.7-8.2] and 20.2 months (95% CI=12.9-25.5), respectively. The objective response rate was 59.0%. Stage IVB disease [hazard ratio (HR)=2.41, p=0.004] and Eastern Cooperative Oncology Group performance status (ECOG PS) score ≥2 (HR=5.10, p=0.007) were significantly associated with shorter PFS. Stage IVB disease (HR=2.29, p=0.014), ECOG PS score ≥2 (HR=15.06, p<0.001), and liver metastasis (HR=3.21, p=0.007) were significantly associated with shorter OS. Stage IVB disease and ECOG PS score ≥2 were independent prognostic factors for both PFS and OS. Prior osimertinib treatment was not significantly associated with either PFS or OS. No unexpected safety signals were observed. Conclusion: ABCP therapy was associated with a median PFS of 6.9 months and median OS of 20.2 months, with no unexpected safety signals in patients with EGFR-mutated NSCLC after EGFR-TKI failure. Stage IVB disease and poor ECOG PS are independent prognostic factors for survival, whereas prior osimertinib treatment is not significantly associated with survival outcomes. Overall, stage IVB disease and poor ECOG PS were associated with survival outcomes, whereas prior osimertinib exposure was not significantly associated with PFS or OS in this cohort.